MAZE vs TMO vs BIO vs CRL vs MEDP vs JPM

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 10. 3x trailing P/E (31. 6x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 10. 3x versus Medpace Holdings, Inc. at 30. 6x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Thermo Fisher Scientific Inc. 's 8. 94x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -52. 9% for Bio-Rad Laboratories, Inc. (BIO). Over 10 years, the gap is even starker: MEDP returned +1582% versus MAZE's +50. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 74β versus Charles River Laboratories International, Inc. 's 1. 39β — meaning CRL is approximately 88% more volatile than BIO relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Thermo Fisher Scientific Inc. 's 8. 94x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 31. 6x for Bio-Rad Laboratories, Inc. — 17. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MAZE: 163. 0% to $63. 25.

In this comparison, JPM (1.

9% yield), TMO (0. 4% yield) pay a dividend. MAZE, BIO, CRL, MEDP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +1582% 10Y return). Both have compounded well over 10 years (MEDP: +1582%, CRL: +122. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MAZE (Healthcare) and TMO (Healthcare) and BIO (Healthcare) and CRL (Healthcare) and MEDP (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAZE is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; BIO is a small-cap deep-value stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while MAZE, TMO, BIO, CRL, MEDP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.